Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
Tell us what YOU think. Take The Body's Visitor Survey!
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy
Safety of Saquinavir Soft Gelatin Capsule (SQV-SGC) with Other Antiviral Agents

Coverage provided by Andrew T. Pavia, M.D.

September 28 - October 1, 1997

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Abstract I -90

A larger trial of the safety and tolerability of the soft gel saquinavir involving 442 patients in an open label study. The patients added SQV-SGC to any pre-existing medications, or preferably, could change the other medications at the same time. After 48 weeks, 70% were still on the study.

Diarrhea occurred in 20% (not much detail on severity), nausea in 11%, heartburn in 8% and flatulence in 8%. Mild to moderate increases in liver enzymes were seen in about 1%.

Taken together with other studies, these two studies suggest that saquinavir in the new formulation is a highly active protease inhibitor. With the increased blood levels and efficacy seem to come some more side effects, but these seem to be mild, manageable (so far) and on a par with other protease inhibitors. It is important to realize that, like the other PI's, using the new saquinavir formulation carelessly will lead to resistance and a once resistance develops to one PI, there is broad cross resistance.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

See Also
More on HIV Medications
More Research on Saquinavir (Fortovase, Invirase)



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement